Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Dec;30(12):1132-1133.
doi: 10.1111/iju.15296. Epub 2023 Sep 4.

Editorial Comment to Identification of tumor immunophenotypes associated with immunotherapy response in bladder cancer

Tibor Szarvas  1   2
Affiliations
Editorial

Editorial Comment to Identification of tumor immunophenotypes associated with immunotherapy response in bladder cancer

Tibor Szarvas. Int J Urol. 2023 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Comment on

References

    1. Ning YM, Suzman D, Maher VE, Zhang L, Tang S, Ricks T, et al. FDA approval summary: Atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum‐containing chemotherapy. Oncologist. 2017;22(6):743–749. - PMC - PubMed
    1. Suzman DL, Agrawal S, Ning YM, Maher VE, Fernandes LL, Karuri S, et al. FDA approval summary: atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin‐containing chemotherapy. Oncologist. 2019;24(4):563–569. - PMC - PubMed
    1. Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218–1230. - PubMed
    1. Evan YY, Petrylak DP, O'Donnell PH, Lee JL, van der Heijden MS, Loriot Y, et al. Enfortumab vedotin after PD‐1 or PD‐L1 inhibitors in cisplatin‐ineligible patients with advanced urothelial carcinoma (EV‐201): a multicentre, single‐arm, phase 2 trial. Lancet Oncol. 2021;22(6):872–882. - PubMed
    1. Liang HQ, Liao NK, Yang SB, Wei QJ, Tan ST, Zhai GQ, et al. Identification of tumor immunophenotypes associated with immunotherapy response in bladder cancer. Int J Urol. 2023. doi: 10.1111/iju.15276 - DOI - PubMed